Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin

Jessica J Manson,1 Kevin Mills,2 Elizabeth Jury,1 Lesley Mason,1 David P D’Cruz,3 Lan Ni,4 Moin Saleem,4 Peter Mathieson,4 David Isenberg,1 Anisur Rahman1


Received 11 January 2014
Revised 10 March 2014
Accepted 14 March 2014

ABSTRACT

Introduction: The tertiary structure of normal podocytes prevents protein from leaking into urine. Patients with lupus nephritis (LN) develop proteinuria, and kidney biopsies from these patients display a number of podocyte abnormalities including retraction of podocyte processes. Autoantibodies have been shown to deposit in the kidneys of patients and mice with LN and are believed to play a key role in causing renal inflammation and dysfunction. The objective of this research was to study the effects of IgG antibodies from patients with LN on cultured human podocytes.

Methods: We exposed a human podocyte cell line to heat-inactivated (HI) plasma and purified polyclonal IgG from the following groups of subjects; patients with LN, patients with lupus without nephritis, patients with rheumatoid arthritis and healthy controls. We measured expression and intracellular distribution of podocyte-specific proteins and global phosphorylation of tyrosine. We then used mass spectrometry to identify the major protein targets of this phosphorylation.

Results: HI LN plasma did not alter expression or cellular distribution of podocyte-specific proteins but caused a significant reduction in podocyte protein tyrosine phosphorylation compared with plasma from healthy controls (p=0.0008). This result was replicated using purified IgG but was not seen with plasma from rheumatoid arthritis or non-renal lupus patients. The dominant tyrosine phosphorylated protein in podocytes was 55 kDa in size and was identified as tubulin.

Conclusions: Since tubulin is an important component of podocyte major processes, these results suggest that autoantibodies from LN patients may exert an important pathogenic effect by dephosphorylation of this protein in podocytes.

INTRODUCTION

The management of patients with lupus nephritis (LN) continues to be dependent on use of corticosteroids and broad spectrum immunosuppressants. Introduction of agents such as rituximab and belimumab, which target specific components of the immune system, may be an improvement. A recent prospective observational study suggested that rituximab may be useful in treating patients with LN without using corticosteroids.1 However, randomised controlled clinical trials have not yet proved the efficacy of either belimumab or rituximab in LN.2–4 An alternative approach would be to study end organ effects by probing the effect of sera from patients with LN on glomerular cells in order to identify novel therapeutic targets. This study was designed to test the hypothesis that pathogenic autoantibodies from patients with systemic lupus erythematosus (SLE) can have a direct effect on the glomerular epithelial cell, the podocyte.

Podocytes are highly specialised cells with interdigitating, tubulin-based, primary and secondary extensions (also termed major processes), and smaller, actin-based, tertiary or foot processes, which are tethered to the glomerular basement membrane by integrin molecules. Maintaining the tertiary structure of the podocyte is critical for preventing the leak of protein into urine. Certain podocyte proteins, notably nephrin, podocin and CD2-associated protein (CD2AP), are critical to this function since lack of any of these proteins in genetic
disorders and/or knockout mice causes severe nephrotic syndrome.\(^5\)\(^-\)\(^7\) A fourth protein, α-actinin 4, is also expressed in podocytes and mutations in this protein are associated with focal segmental glomerulosclerosis.\(^8\) Antibodies to α-actinin have been suggested to play a pathogenic role in LN based on both murine and clinical studies,\(^9\)\(^-\)\(^11\) though more recent evidence from clinical studies\(^12\) and electron microscopy of renal biopsies from human and murine LN did not support this hypothesis.\(^13\)\(^-\)\(^14\)

Patients with LN almost always present with proteinuria and have podocyte abnormalities on biopsy.\(^15\) Furthermore, the degree of podocyte pathology, as measured by foot process effacement, correlates with proteinuria.\(^16\) More recently, Persynsaki et al\(^17\) showed a correlation between increased foot process effacement, reduced glomerular expression of nephrin and podocin and progressive worsening of histological nephritis and proteinuria in both NZB/W F1 mice and patients with LN. The presence of immune deposits in a subepithelial distribution (ie, around the podocyte), as seen in membranous LN, is associated with more severe proteinuria. It is not known, however, whether podocytes are targeted directly by autoantibodies.\(^18\) There is evidence that exposure to plasma from children with nephrotic syndrome can cause relocation and altered expression of nephrin, podocin and CD2AP in cultured human podocytes.\(^19\) This study only included one patient (aged 14) with LN. There is no similar evidence using samples from adult patients or purified IgG from either children or adults with LN.

In the context of SLE, it is the immunoglobulin fraction of plasma that is of particular interest, as generation of autoantibodies is considered to be critical in disease pathogenesis. There are observational data from human studies (reviewed in\(^20\)) and experimental data from murine models\(^21\)\(^-\)\(^22\) to support the concept that these antibodies can be directly pathogenic. Here, we describe a series of experiments investigating the effects of plasma and purified IgG on cultured human podocytes. We compared effects of plasma samples from patients with LN, patients with non-renal lupus, patients with rheumatoid arthritis and healthy control subjects. In particular, we looked for effects on expression, distribution and tyrosine phosphorylation of key podocyte proteins.

### IgG purification

IgG was purified from plasma samples using HiTrap Protein G Columns (GE Healthcare). Aliquots of IgG were tested for LPS using the E-Toxate kit (Sigma), and samples that tested positive were treated with Detoxi-Gel Endotoxin Removing columns (Pierce). The concentration of IgG was confirmed in an IgG ELISA as described previously.\(^23\)

### Plasma and IgG exposure experiments

The conditionally immortalised human podocytes were cultured as described previously.\(^24\) Fully differentiated podocytes were then exposed to medium containing heat-inactivated (HI) human plasma, or purified IgG, for a prespecified time—5 min to 48 h. Thereafter, cells were trypsinised, washed in ice cold PBS and lysed in ice cold lysis buffer. Lysates were stored at −80°C.

### Immunofluorescence microscopy

Podocytes were cultured on sterile coverslips in medium containing plasma from LN patients or from healthy controls. After 48 h exposure of the podocytes to plasma, the effect on the localisation of α-actinin and CD2AP was determined by immunofluorescent staining. Cells were fixed with paraformaldehyde and permeabilised with triton-X 100. Non-specific binding was blocked with 2% FCS/2% BSA/0.1% Tween/PBS containing 10% normal rabbit serum (sigma), and then cells were incubated with the primary antibodies (rabbit-anti-α-actinin-4 (ImmunoGlobe), rabbit-anti-CD2AP (Santa Cruz Biotechnology)). After washing, goat antirabbit IgG-FITC conjugate (Sigma) was added and the coverslips were mounted on glass slides using Mowiol mountant. The slides were viewed on a Biorad confocal microscope and images captured using LaserSharp 2000 and analysed using confocal assistant V4.02 software.

### Western blot analysis

Changes in protein expression and phosphorylation were assessed by western blotting. Equal amounts of protein (30 μg per well) were separated on SDS-polyacrylamide gels. Proteins were electrophoretically transferred onto methanol activated polyvinylidene

### PATIENTS AND METHODS

#### Patients and controls

This study received approval from the Thames Valley Multi-Centre Research Ethics Committee. Patients and age/sex matched healthy controls were recruited from the University College Hospital and St Thomas’ Hospital, London, after receiving informed written consent. Blood was collected in heparinised tubes spun at 4°C, 500 g for 10 min and then plasma was stored at −20°C. Demographic information about all the patients with LN, and the healthy and disease controls, is summarised in **Table 1**. More detailed information about the patients with LN is given in **Table 2**.

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean age* (range)</th>
<th>Sex</th>
<th>Ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lupus nephritis (n=17)</td>
<td>32 (18–56)</td>
<td>1F</td>
<td>7A, 3B, 7W</td>
</tr>
<tr>
<td>Non-renal lupus (n=5)</td>
<td>40 (30–64)</td>
<td>5F</td>
<td>1A, 4W</td>
</tr>
<tr>
<td>Rheumatoid arthritis (n=5)</td>
<td>62 (40–78)</td>
<td>3F</td>
<td>5W</td>
</tr>
<tr>
<td>Normal controls (n=30)</td>
<td>39 (24–64)</td>
<td>24F</td>
<td>4A, 5B, 21W</td>
</tr>
</tbody>
</table>

*Age in years.
A, Asian; B, Black; F, female; M, male; W, White.
difluoride (PVDF) membranes (Millipore). Following blocking, membranes were probed with antiphosphotyrosine (Upstate), antipodocin (Santa Cruz), antinephrin (kind gift of Dr Lawrence Holzman), anti-CD2AP (Santa Cruz), actin (Sigma) and anti-GAPDH (Chemicon) antibodies. Visualisation of the protein bands was achieved using horseradish peroxidase (HRP)-conjugated secondary antibodies and chemiluminescence. Expression of podocin, nephrin, CD2AP and tyrosine phosphorylated proteins was quantified by normalising the strength of the relevant protein band to that of the housekeeping protein (actin or GAPDH) measured on the same gel using densitometry.

Immunoprecipitation

Tyrosine phosphorylated podocyte proteins were isolated using an antiphosphotyrosine antibody bound to protein G beads (Amersham, UK). Cell lysates were clarified by centrifugation, then added to the washed beads, along with protease and phosphatase inhibitors, and left to bind overnight.

Following a brief spin, the supernatant was removed and the beads washed in ice-cold lysis buffer. The pellet was resuspended in Laemmli sample buffer containing 2-mercaptoethanol. Bound proteins were released by boiling and run on an SDS-polyacrylamide gel. Protein bands were visualised by silver staining and were carried out using a Silver Stain Plus Kit (Bio-Rad, UK), as per the manufacturer’s instructions.

Mass spectrometry

Relevant protein bands were cut out of the polyacrylamide gel and partially dehydrated using acetonitrile (ACN). The ACN was discarded and the gel pieces were dehydrated completely by centrifugal evaporation. Samples were reduced with dithiothreitol and alkylated with iodoacetamide. In-gel trypsinisation was followed by release of peptides using trifluoroacetic acid. Peptides were separated out on a 25 cm C18 Aqua HPLC column prior to mass spectrometry. Continuum LC-MS data were processed and searched using ProteinLynx GlobalServer versions 2.2.5 and 2.3 (Waters, UK). Protein identifications were obtained by searching the human entries of the UniProt/Swiss-Prot (V.53.5) database, and the presence/position of tyrosine phosphorylation sites investigated using the Phosphosite database (http://www.phosphosite.org).

Statistics

Data were analysed using non-parametric statistical tests using GraphPad Prism.

RESULTS

Position, expression and phosphorylation of podocyte proteins following exposure to plasma from LN patients or healthy controls

Plasma obtained from six patients with LN and six healthy donors was heat inactivated to remove viable cytokines and complement but retain immunoglobulins. The six patients whose samples were used in this part of the study were LN4, LN8, LN9, LN10, LN11 and LN17. They were chosen because they were among the earliest samples available in this study and not on the basis of particular clinical characteristics. The cellular distributions of α-actinin-4 and CD2AP, both proteins important for podocyte function, were examined by immunofluorescence

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Sex</th>
<th>Age</th>
<th>Ethnicity</th>
<th>Biopsy result</th>
<th>Urine PCR (mg/mmol)</th>
<th>Serum albumin (g/L)</th>
<th>Treatment at time of biopsy* (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LN1</td>
<td>F</td>
<td>49</td>
<td>Asian</td>
<td>III</td>
<td>58</td>
<td>38</td>
<td>P20, H400</td>
</tr>
<tr>
<td>LN2</td>
<td>F</td>
<td>34</td>
<td>White</td>
<td>IV,V</td>
<td>457</td>
<td>30</td>
<td>P20, MP</td>
</tr>
<tr>
<td>LN3</td>
<td>F</td>
<td>20</td>
<td>Black</td>
<td>V</td>
<td>123</td>
<td>28</td>
<td>P30, H400</td>
</tr>
<tr>
<td>LN4</td>
<td>F</td>
<td>31</td>
<td>White</td>
<td>IV</td>
<td>533</td>
<td>21</td>
<td>P10, H400, M1500</td>
</tr>
<tr>
<td>LN5</td>
<td>F</td>
<td>30</td>
<td>White</td>
<td>V</td>
<td>569</td>
<td>23</td>
<td>P10, H400</td>
</tr>
<tr>
<td>LN6</td>
<td>F</td>
<td>35</td>
<td>Black</td>
<td>III</td>
<td>202</td>
<td>30</td>
<td>P5, C</td>
</tr>
<tr>
<td>LN7</td>
<td>F</td>
<td>29</td>
<td>Asian</td>
<td>III</td>
<td>96</td>
<td>20</td>
<td>P15, A100</td>
</tr>
<tr>
<td>LN8</td>
<td>F</td>
<td>33</td>
<td>Asian</td>
<td>III/V</td>
<td>208</td>
<td>36</td>
<td>P12.5, H200</td>
</tr>
<tr>
<td>LN9</td>
<td>F</td>
<td>27</td>
<td>Asian</td>
<td>III</td>
<td>34</td>
<td>28</td>
<td>P60, C</td>
</tr>
<tr>
<td>LN10</td>
<td>F</td>
<td>18</td>
<td>Asian</td>
<td>IV</td>
<td>66</td>
<td>44</td>
<td>P10, M2000</td>
</tr>
<tr>
<td>LN11</td>
<td>M</td>
<td>19</td>
<td>Asian</td>
<td>IV</td>
<td>1017</td>
<td>17</td>
<td>P20, M1000, C</td>
</tr>
<tr>
<td>LN12</td>
<td>F</td>
<td>43</td>
<td>White</td>
<td>I</td>
<td>312</td>
<td>34</td>
<td>H400</td>
</tr>
<tr>
<td>LN13</td>
<td>F</td>
<td>48</td>
<td>White</td>
<td>II</td>
<td>127</td>
<td>33</td>
<td>H400, MP</td>
</tr>
<tr>
<td>LN14</td>
<td>F</td>
<td>34</td>
<td>White</td>
<td>V</td>
<td>366</td>
<td>34</td>
<td>P20, A100</td>
</tr>
<tr>
<td>LN15</td>
<td>F</td>
<td>56</td>
<td>White</td>
<td>III/V</td>
<td>88</td>
<td>43</td>
<td>P5, A100</td>
</tr>
<tr>
<td>LN16</td>
<td>F</td>
<td>28</td>
<td>Black</td>
<td>IV/V</td>
<td>297</td>
<td>37</td>
<td>P20</td>
</tr>
<tr>
<td>LN17</td>
<td>F</td>
<td>21</td>
<td>Asian</td>
<td>IV</td>
<td>65</td>
<td>43</td>
<td>P15, A 150</td>
</tr>
</tbody>
</table>

*In a number of cases, the treatment was changed as a result of the biopsy (eg, the addition of immunosuppressant drugs to high-dose corticosteroids) but those drugs are not included in the table as they would have no effect on samples taken before the drug was started, that is, at the time of the biopsy.

(M)P, (methyl)prednisolone; A, azathioprine; C, cyclophosphamide; H, hydroxychloroquine; LN, lupus nephritis; M, mycophenolate mofetil; PCR, protein creatinine ratio.
following 48 h culture with HI plasma from patients and controls (figure 1A, B, D and E show representative immunofluorescence images). The characteristic peripheral pattern of staining for CD2AP and α-actinin-4 was assessed; however, quantitative analysis revealed no significant difference between podocytes exposed to plasma from LN patients compared with healthy donors (figure 1C, F).

Next, we assessed the effect of exposing podocytes to healthy and LN plasma over a time course (5 min, 30 min, 1 h, 4 h, 14 h, 24 h and 48 h). No differences in the total expression of α-actinin-4, CD2AP or podocin at any of the time points assayed were observed by western blotting (data not shown).

However, a significant reduction in global protein tyrosine phosphorylation was observed in podocytes exposed to plasma from LN patients compared with the effect of plasma from healthy controls after 24 h culture (p=0.0008) (figure 2). By 48 h, differences between the groups were no longer seen (figure 2).

This observation was specific to LN patients since similar changes were not observed when podocytes were exposed to plasma from patients with rheumatoid arthritis (a disease where podocyte pathology is not observed) or from patients with SLE, but with no history of renal involvement (figure 3A–C). In addition, this effect appeared to be specific to podocytes since no changes in protein tyrosine phosphorylation were observed when cells from an irrelevant epithelial line (HeLa cells) were cultured in medium containing plasma from LN patients (data not shown).

Thus, the results indicated that only plasma from LN patients contained a factor that influenced tyrosine phosphorylation of podocyte proteins.

Tyrosine phosphorylation of podocyte proteins following exposure to purified IgG

In order to prove that antibodies, rather than any other plasma component, were responsible for influencing protein tyrosine phosphorylation, IgG was purified from LN and healthy control plasma samples. Podocytes were grown in medium containing purified IgG at two concentrations: 100 μg/mL, a concentration typically used in experiments with monoclonal antibodies, and 1.5 mg/mL to mirror the amount of IgG present in the plasma exposure experiments. Exposing podocytes to purified IgG from patients with LN at the higher (1.5 mg/mL) (figure 4B), but not at the lower (100 μg/mL) concentration (figure 4A), led to a relative decrease in tyrosine phosphorylation compared with IgG from healthy donors, thus recapitulating the initial plasma exposure experiments (p=0.001).

In order to prove that antibodies, rather than any other plasma component, were responsible for influencing protein tyrosine phosphorylation, IgG was purified from LN and healthy control plasma samples. Podocytes were grown in medium containing purified IgG at two concentrations: 100 μg/mL, a concentration typically used in experiments with monoclonal antibodies, and 1.5 mg/mL to mirror the amount of IgG present in the plasma exposure experiments. Exposing podocytes to purified IgG from patients with LN at the higher (1.5 mg/mL) (figure 4B), but not at the lower (100 μg/mL) concentration (figure 4A), led to a relative decrease in tyrosine phosphorylation compared with IgG from healthy donors, thus recapitulating the initial plasma exposure experiments (p=0.001).
Identification of proteins with variable tyrosine phosphorylation

Examination of the western blots shown in figure 2A revealed dominant tyrosine phosphorylated protein bands at approximately 55 and 80 kDa. In order to understand the functional implications of the observed dephosphorylation, the tyrosine phosphorylated proteins were isolated by immunoprecipitation using an antiphosphotyrosine antibody before separation on polyacrylamide gels, and the protein bands visualised by silver staining (figure 5). The proteins of interest, and a number of control bands, were excised from the polyacrylamide gel and subjected to in-gel proteolytic digestion before analysis and identification using electrospray QTOF mass spectrometry. A number of tyrosine phosphorylated proteins were obtained from the bands. However, apart from the expected contaminants—keratin, trypsin and IgG—the results revealed two specific proteins: tubulin in the 55 kDa band and glucose-regulated protein 78 (GRP78) in the 80 kDa band (see table 3). The results were confirmed since the proteins were isolated in the replicate sample, but not in any of the control bands, and were of the correct molecular weight.

Analysis of the spectra obtained from the mass spectrometry sequence data for tubulin added further support to the validity of the finding, in that there was a low signal-to-noise ratio, and that the isolated peptide had an identical amino acid sequence when read in either direction.

All proteins were sequenced using electrospray QTOF-MS, except trypsin and keratin, if number of matches ≥3.

DISCUSSION

These experiments were designed to investigate possible mechanisms by which IgG from patients with LN could have a direct effect on podocytes. Our key finding is that growing podocytes in medium containing plasma or purified IgG from patients with active LN for 24 h leads to reduced tyrosine phosphorylation of podocyte proteins, and the effect of purified IgG is dose dependent. This effect is seen only with samples from patients with active LN and not with IgG from non-nephritic lupus. These same LN samples had no similar effect on an irrelevant cell line. Importantly, these changes in phosphorylation were reversible, demonstrating that the cells were not simply killed, and normal levels of phosphorylation were noted by 48 h. In particular, tubulin, a protein known to play a key role in maintaining the structure of podocytes, was identified among the proteins that were dephosphorylated. Ideally, these results could be further confirmed by carrying out western blots with specific antibodies to tyrosine phosphorylated...
forms of tubulin. However, no such antibodies are available.

There are a number of limitations to our experiments. First, we exposed podocytes to IgG for a limited period only as the culture was not replenished with IgG following addition of the culture medium at time 0. In vivo, autoantibodies would be present continuously as they have been shown to deposit in chromatin-rich areas near podocytes by electron microscopy.\textsuperscript{13, 14} Thus, rather than the transient effect on tyrosine phosphorylation that we have shown in vitro, we propose that there would be a longer lasting effect in vivo, which could contribute to the pathogenesis of LN. This might be investigated, for example, by using immunofluorescence to look for reduced tyrosine phosphorylation of podocyte proteins in renal biopsies from human or murine LN. Although we showed no effect on podocyte tyrosine phosphorylation exerted by serum from patients with rheumatoid arthritis or non-renal lupus, we did not have access to samples from patients with other forms of autoimmune nephritis. It would be interesting to compare the effects of serum and IgG from those patients with the effects of LN IgG and also to see whether the effect in LN is specific to particular IgG isotypes and/or varies with the histological class of LN or with degree of proteinuria. Finally, for pragmatic reasons (the amount of serum and IgG that we could obtain from individual donors under the conditions of our ethics approval), the normal control (NC) samples used were not the same in all parts of the experiment and there is thus a variation in the results obtained from NC in different figures of the results section. Although an imperfect compromise, use of densitometry and normalisation to actin or GAPDH does reduce the effect of this variation and shows statistically significant differences between LN and NC samples.

Changes in phosphorylation of tubulin alter podocyte morphology. Polymerisation of tubulin is important in the formation of thick tubular structures that support the major processes of podocytes.\textsuperscript{26} These tubulin-

Figure 3  Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus.

Representative antiphosphotyrosine blots from experiments comparing the effect of growing podocytes for 24 h in normal control (NC) plasma versus plasma from patients with LN (A), rheumatoid arthritis (RA, B) or non-renal systemic lupus erythematosus (NR-SLE, C). Cells were lysed and protein tyrosine phosphorylation assessed by western blot. The graphs display densitometry, with the median and IQR for each group. Medians were compared using the Mann–Whitney test. As already shown, LN plasma leads to a reduction in protein tyrosine phosphorylation, whereas the effect of plasma from patients with RA or NR-SLE is no different to NC. Equal loading was ensured by blotting for either actin or GAPDH.
containing major processes connect the podocyte cell body with the actin network of the foot processes. Inhibition of microtubule function using vinblastine causes collapse and thinning of podocyte major processes, but leaves the actin-based foot processes unaffected. Xing et al. reported that exposure to dexamethasone promotes maturation and process formation of cultured human podocytes in vitro and that this is associated with increased expression of tubulin and nephrin but not podocin or CD2AP. Although these authors did not look at tyrosine phosphorylation of tubulin or other podocyte proteins, there is evidence that this process is important in podocyte function. In the normal rat kidney, tyrosine phosphorylated proteins are concentrated in the glomerulus, particularly the podocyte foot processes. Furthermore, treatment of cultured mouse podocytes with protamine sulfate or puromycin aminonucleoside caused retraction of podocyte cell processes, increase in cytoplasmic staining of tyrosine phosphorylated proteins and a reduction of tyrosine phosphorylation at focal contacts.

Tyrosine phosphorylation of tubulin by the tyrosine kinase Fes promotes the formation of microtubule-like polymers. This may have implications for cell differentiation as shown in a study of myelocytic leukemic HL-60 cells. Induction of differentiation using tetradecanoyl phorbol acetate led to increased tyrosine phosphorylation of tubulin α and β, stretching of microtubules and the development of cell projections. In contrast to the evidence that increased tyrosine phosphorylation promotes microtubule formation, there is less evidence relating to reduced phosphorylation. Kobayashi et al. used a conditionally immortalised mouse cell line to demonstrate that microtubule elongation and major podocyte process formation was inhibited following suppression of serine/threonine phosphatase activity by treatment with okadaic acid. By contrast, cells treated with vanadate, which inhibits tyrosine phosphorylation, did develop processes, although with fewer cell contacts, and at higher concentrations, vanadate caused cell detachment. The finding that the serine/threonine phosphatase PP2A is absent in adult kidney might suggest a greater role for tyrosine phosphorylation in the mature podocyte.

We also detected tyrosine phosphorylation of GRP78 in podocytes. GRP78, also known as binding immunoglobulin protein (BiP), is involved in endoplasmic reticulum stress, which involves attenuation of new protein synthesis and degradation of misfolded proteins. GRPs play a key role in the latter process by binding to defective proteins and marking them out for degradation. As terminally differentiated cells, podocytes require a well-developed adaptive response to stress and there is evidence linking GRP78 to podocyte dysfunction. Inagi et al. studied megsin transgenic rats, in which overexpression and accumulation of megsin in podocytes leads to cell damage, proteinuria and renal impairment. By immunohistochemistry they demonstrated marked upregulation of GRP78 in glomeruli of these rats. GRP78 has also been shown to be upregulated in renal biopsies from patients with focal nephritis.
segmental glomerulosclerosis and membranoproliferative glomerulonephritis. Mice carrying a mutation in BiP developed tubular interstitial injury, which is accelerated by protein overload. However, there is no information in mice, humans or rats regarding any effect of tyrosine phosphorylation on the function of GRP78.

We did not see any effect on total expression of CD2AP, podocin or α-actinin-4 in podocytes exposed to IgG or plasma from patients with LN despite testing this at a wide range of time points. There is conflicting evidence on overall expression of podocyte proteins in LN in the literature. Koop et al found that expression of nephrin and podocin was reduced at the protein level

but increased at the mRNA level in renal tissue from seven patients with LN compared with 13 healthy kidneys. Perysinaki et al found that expression was dependent on the histological type of nephritis. In NZB/W F1 mice, nephrin and podocin expression were both reduced at both protein and mRNA level in proliferative nephritis but only nephrin was reduced in mesangial disease. In human renal biopsies, nephrin expression was normal in type II LN but reduced in type IV or V. Thus, the expression of these proteins may be affected by the structural milieu within the inflamed kidney, which would not be reproduced in our experiments on cultured cells.

Coward et al showed that the characteristic peripheral distribution of CD2AP in the same cultured human podocyte line that we used was disrupted by addition of nephrotic syndrome plasma (but not healthy control plasma) and postulated that this disruption was important in altering podocyte function. In contrast, we found that LN plasma did not cause translocation of podocyte slit diaphragm proteins away from the cell membrane. The patients studied by Coward et al were all children with nephrotic syndrome severe enough to require plasma exchange and only one had SLE. Our patients were all adults and had much less severe proteinuria. None had plasma exchange. Our results do not exclude the possibility that plasma samples from adults with severe LN might produce the same effects on protein distribution seen by Coward et al, but suggest that at earlier and less severe stages of LN a different mechanism operates.

We propose a mechanism in which IgG from patients binds directly to podocytes, leading to changes in phosphorylation of key structural proteins (especially tubulin), which alters morphology and function of the cells. IgG from patients with SLE have previously been shown to bind more strongly to human mesangial cells and pleural mesothelial cells than IgG from healthy controls. Affinity purified anti-DNA antibodies have been shown to bind to surface annexin II on a human mesangial cell line, following which they become internalised, causing activation of cell kinases and increased production of the pro-inflammatory cytokine IL-6.

**CONCLUSION**

In summary, these results suggest that pathogenic IgG in patients with LN interact directly with podocytes to cause changes in intracellular tyrosine phosphorylation of proteins such as tubulin. Further investigation of this mechanism could be important in the identification of novel treatments that do not rely upon immunosuppression.

**Contributors** JJM and AR conceived the idea of the project and wrote the final paper. JJM and LM carried out the laboratory experiments on human podocytes. AR, DI and DDC recruited patients and obtained clinical details. EJ took part in the cell culture and immunological experiments. KM took part in the mass spectrometry experiments. LN, MS and PM developed the human podocyte line and method for assessing staining of podocyte specific proteins

**Table 3** Summary of proteins identified for each sample

<table>
<thead>
<tr>
<th>Band number (see gel in figure 5)</th>
<th>Approximate molecular weight (kDa)</th>
<th>Isolated proteins (species)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>40</td>
<td>Actin</td>
</tr>
<tr>
<td>2</td>
<td>80</td>
<td>GRP78 (multiple)</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
<td>IgG2β (mouse)</td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>IgG2β (mouse), tubulin α (multiple), tubulin β (multiple)</td>
</tr>
<tr>
<td>5</td>
<td>25</td>
<td>IgGκ (mouse)</td>
</tr>
</tbody>
</table>
using immunofluorescence. All authors reviewed and agreed on the final manuscript.

**Funding**
This work was funded by Arthritis Research UK Research Grants 16555 and 17045 and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funders had no role in the acquisition or analysis of the data or writing the manuscript.

**Competing interests**
None.

**Ethics approval**
Thames Valley Multi-Centre Research Ethics Committee.

**Provenance and peer review**
Not commissioned; externally peer reviewed.

**Data sharing statement**
No additional data are available.

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.

**REFERENCES**


